Cover - USD ($) $ in Millions |
12 Months Ended | ||
|---|---|---|---|
Dec. 31, 2025 |
Mar. 19, 2026 |
Jun. 30, 2025 |
|
| Document Information [Line Items] | |||
| Document Type | 10-K | ||
| Amendment Flag | false | ||
| Document Annual Report | true | ||
| Document Transition Report | false | ||
| Document Period End Date | Dec. 31, 2025 | ||
| Document Fiscal Period Focus | FY | ||
| Document Fiscal Year Focus | 2025 | ||
| Current Fiscal Year End Date | --12-31 | ||
| Entity File Number | 001-37648 | ||
| Entity Registrant Name | Insight Molecular Diagnostics Inc. | ||
| Entity Central Index Key | 0001642380 | ||
| Entity Tax Identification Number | 27-1041563 | ||
| Entity Incorporation, State or Country Code | CA | ||
| Entity Address, Address Line One | 2 International Plaza Dr., Suite 510 | ||
| Entity Address, City or Town | Nashville | ||
| Entity Address, State or Province | TN | ||
| Entity Address, Postal Zip Code | 37217 | ||
| City Area Code | (615) | ||
| Local Phone Number | 255-8880 | ||
| Title of 12(b) Security | Common Stock, no par value | ||
| Trading Symbol | IMDX | ||
| Security Exchange Name | NASDAQ | ||
| Entity Well-known Seasoned Issuer | No | ||
| Entity Voluntary Filers | No | ||
| Entity Current Reporting Status | Yes | ||
| Entity Interactive Data Current | Yes | ||
| Entity Filer Category | Non-accelerated Filer | ||
| Entity Small Business | true | ||
| Entity Emerging Growth Company | false | ||
| Entity Shell Company | false | ||
| Entity Public Float | $ 32.4 | ||
| Entity Common Stock, Shares Outstanding | 32,167,978 | ||
| Documents Incorporated by Reference [Text Block] | DOCUMENTS INCORPORATED BY REFERENCE Portions of the registrant’s Proxy Statement for its 2026 Annual Meeting of Shareholders (the “Proxy Statement”), to be filed with the Securities and Exchange Commission (“SEC”) within 120 days after the end of the fiscal year ended December 31, 2025, are incorporated herein by reference in Part III of this Annual Report on Form 10-K. |
||
| ICFR Auditor Attestation Flag | false | ||
| Document Financial Statement Error Correction [Flag] | false | ||
| Auditor Name | CBIZ CPAs P.C. | ||
| Auditor Firm ID | 199 | ||
| Auditor Location | Costa Mesa, CA | ||
| Auditor Opinion | Opinion on the Financial Statements We have audited the accompanying consolidated balance sheet of Insight Molecular Diagnostics Inc. (the “Company”) as of December 31, 2025, the related consolidated statements of operations, comprehensive loss, Series A redeemable convertible preferred stock and stockholders’ deficit, and cash flows for the year ended December 31, 2025 and the related notes (collectively referred to as the “financial statements”). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2025, and the results of its operations and its cash flows for the year ended December 31, 2025, in conformity with accounting principles generally accepted in the United States of America. |